MedDRA preferred term

Product distribution issue: adverse event reports recording this term

8,745 reports to FDA record it, 2011–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

8,745
reports recording the term: 0% of all reports; 1,951
reports, 12 months to June 2026: 1,676 in the 12 months before; 37.2%
marked serious by the reporter: 57.4% across all reports; 1.8%
record death among outcomes, as reported: 9.1% across all reports

8,745 reports in FDA's adverse event database record the MedDRA term "Product distribution issue": 0% of all reports received between July 2011 and June 2026. Coders pick the term that best matches the reporter's description.

1,951 reports recorded it in the 12 months to June 2026, up 16% from 1,676 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 37.2% are marked serious, 1.8% include death among the outcomes and 15.2% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Revlimid, Lenalidomide and Cosentyx. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Revlimid	Thalidomide analog	756	0.2%
Lenalidomide	Thalidomide analog	426	0.7%
Cosentyx	Interleukin-17A antagonist	350	0.2%
Pomalyst	Thalidomide analog	338	0.4%
Jakafi	Janus kinase inhibitor	313	0.6%
Cimzia	Tumor necrosis factor blocker	267	0.3%
Nuplazid	Atypical antipsychotic	251	0.5%
Orgovyx	Gonadotropin releasing hormone receptor antagonist	246	1.1%
Human immunoglobulin g	Human immunoglobulin G	211	1.2%
Certolizumab pegol	Tumor necrosis factor blocker	179	0.7%
Vedolizumab	Integrin receptor antagonist	173	0.3%
Teduglutide	GLP-2 analog	144	1.6%
Orencia	Selective T cell costimulation modulator	131	0.1%
Bimzelx	—	130	0.8%
Kesimpta	CD20-directed cytolytic antibody	112	0.4%
Humira	—	100	0%
Epidiolex	—	88	0.5%
Bimekizumab	—	83	2.1%
Haegarda	—	82	1.7%
Enbrel	Tumor necrosis factor blocker	80	0%
Lanadelumab	—	79	3.6%
Xifaxan	Rifamycin antibacterial	77	0.6%
Human Immunoglobulin G Hyaluronidase Recombinant Human	—	76	2%
BOTOX Cosmetic	Acetylcholine release inhibitor	65	0.2%
Skyrizi	Interleukin-23 antagonist	65	0.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Thalidomide analog	1,547	0.3%	0.3%
Tumor necrosis factor blocker	687	0.1%	0%
Interleukin-17A antagonist	364	0.2%	0%
Janus kinase inhibitor	362	0.1%	0%
Human immunoglobulin G	333	0.5%	0%
Atypical antipsychotic	268	0%	0%
Gonadotropin releasing hormone receptor antagonist	253	0.9%	0.3%
Integrin receptor antagonist	213	0.1%	0.1%
Kinase inhibitor	180	0%	0%
GLP-2 analog	151	1.1%	0.9%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.2%15

2 to 111.5%135

12 to 171.2%101

18 to 4411.8%1,034

45 to 6419.8%1,730

65 to 7413.7%1,196

75 and over11.8%1,030

Age not given40.1%3,504

Patient sex

Female47.5%4,153

Male34.5%3,015

Not given18%1,577

Grey bar: all 20,646,523 reports in the database. 87.5% of these reports give the United States as the country.

Questions about "Product distribution issue"

What does "Product distribution issue" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record product distribution issue?

8,745 reports through June 2026 (0% of all reports), 1,951 of them in the latest 12 months.

Which drugs appear most often in these reports?

Revlimid (756), Lenalidomide (426), Cosentyx (350), Pomalyst (338) and Jakafi (313). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.